Group 1 - Tenglong Co., Ltd. has small batch products indirectly applied in data center/server liquid cooling and energy storage liquid cooling fields [1] - Fuyao Glass reported a 37.33% year-on-year increase in net profit for the first half of 2025, reaching 4.805 billion yuan [2] - Huihong Group plans to dispose of certain financial assets, including stocks of Hongye Futures, Zhongtai Securities, and Shengyi Technology, to optimize asset structure [3] Group 2 - Zhongheng Electric clarified that it has not signed cooperation agreements with overseas cloud companies like NVIDIA, Meta, and Google [4] - Kosen Technology announced it does not produce robot products, despite recent stock price fluctuations [5] - Garden Shares stated it does not have a controlling relationship with Yunzhin Technology [6] Group 3 - Yiling Pharmaceutical's new drug application for "Children's Lianhua Qinggan Granules" has been accepted by the National Medical Products Administration [7] - Zhuochuang Information plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange [8] - Lianhuan Pharmaceutical's new oral solution production line has passed GMP compliance inspection [9] Group 4 - Xianda Co., Ltd. reported a 2561.58% year-on-year increase in net profit for the first half of 2025, reaching 136 million yuan [10] - Jiangte Motor announced that its subsidiary Yichun Silver Lithium will resume production soon [11] - Dameng Data's board member and general manager is under investigation [12] Group 5 - Dongjie Intelligent is planning a change in control, leading to a suspension of its stock and convertible bonds [13] - Gibit reported a 24.50% year-on-year increase in net profit for the first half of 2025, amounting to 645 million yuan [14] - Wuzhou Special Paper's net profit decreased by 47.57% year-on-year to 122 million yuan [15] Group 6 - Harbin Air Conditioning reported a loss of 7.64 million yuan for the first half of 2025, reversing from profit [16] - Tibet Tourism achieved a net profit of 2.09 million yuan, turning around from a loss of 2.58 million yuan in the previous year [17]

主要结论：根据《中华人民共和国行政许可法》第三十二条的规定，经审查， 决定予以受理。 证券代码：002603 证券简称：以岭药业 公告编号：2025-030 石家庄以岭药业股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 近日，石家庄以岭药业股份有限公司（以下简称"公司"）收到国家药品监 督管理局下发的《受理通知书》，由公司提交的"小儿连花清感颗粒"新药注册 上市申请已获正式受理。现就相关事项公告如下： 一、受理通知书基本内容 申 请 人：石家庄以岭药业股份有限公司 申请事项：境内生产药品注册上市许可 产品名称：小儿连花清感颗粒 受 理 号：CXZS2500034 二、药品的基本情况 小儿连花清感颗粒是公司自主研制的中药创新药，其功能主治为：清感解表， 宣肺泄热。用于儿童急性上呼吸道感染风热感冒证，症见发热，鼻塞，咽喉肿痛， 咳嗽，恶风，喷嚏、流涕，头痛，肌肉酸痛，舌淡红或红，苔薄黄，脉浮数。 三、对公司的影响及主要风险提示 根据国家药品注册相关的法律法规要求，上述药品在获国家药品监督管理局 注册申请受理后将转入国家药品监督管理局药品审评中心接受技 ...

证券日报网讯 8月19日晚间，以岭药业发布公告称，近日，公司收到国家药品监督管理局下发的《受理 通知书》，由公司提交的"小儿连花清感颗粒"新药注册上市申请已获正式受理。 （文章来源：证券日报） ...

Group 1: Company Announcements - Tenglong Co., Ltd. has small batch products indirectly applied in data center/server liquid cooling and energy storage liquid cooling, with sales and development revenue of approximately 0.8 million yuan for electronic water pump products and 0.97 million yuan for hose products, which have a small impact on the company's financial statements [1] - Fuyao Glass reported a net profit of 4.805 billion yuan for the first half of 2025, a year-on-year increase of 37.33%, with total revenue of 21.447 billion yuan, up 16.94% [2] - Huihong Group plans to dispose of certain financial assets, including shares in Hongye Futures and Zhongtai Securities, to optimize asset structure and improve operational efficiency [3] Group 2: Market Reactions and Clarifications - Zhongheng Electric clarified that it has not signed any cooperation agreements with overseas cloud service providers like Nvidia, Meta, or Google, despite recent rumors [4] - Kosen Technology stated that it does not manufacture robot products, addressing media misclassification as a robotics company [5] - Garden Shares confirmed that it does not have a controlling relationship with Yunzhin Technology, holding only a 15% stake, and that the latter is still in the early stages of technology transformation [6] Group 3: New Product Developments - Yiling Pharmaceutical's new drug application for "Children's Lianhua Qinggan Granules" has been accepted by the National Medical Products Administration, aimed at treating acute respiratory infections in children [7] - Zhuochuang Information plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange, with details yet to be finalized [9] - Lianhuan Pharmaceutical's new oral solution production line has passed the GMP compliance inspection, with an investment of approximately 7.5 million yuan [10] Group 4: Financial Performance - Xianda Co., Ltd. reported a net profit of 136 million yuan for the first half of 2025, a year-on-year increase of 2561.58%, driven by significant price increases in its main product [11] - Jibite achieved a net profit of 645 million yuan, up 24.50% year-on-year, with a proposed cash dividend of 6.6 yuan per 10 shares [15] - Wuzhou Special Paper reported a net profit of 122 million yuan, down 47.57% year-on-year, affected by market supply and demand [16]

Core Viewpoint - Yiling Pharmaceutical has received a formal acceptance notice from the National Medical Products Administration for its new drug registration application of "Xiaoer Lianhua Qinggan Granules," indicating progress in the company's innovative drug development for pediatric use [1] Group 1: Product Information - "Xiaoer Lianhua Qinggan Granules" is an innovative traditional Chinese medicine developed by the company [1] - The drug is indicated for the treatment of acute upper respiratory tract infections in children, specifically for symptoms such as fever, nasal congestion, sore throat, cough, aversion to wind, sneezing, runny nose, headache, muscle aches, pale red or red tongue, thin yellow coating, and floating rapid pulse [1]

格隆汇8月19日丨以岭药业（维权）(002603.SZ)公布，近日，石家庄以岭药业股份有限公司收到国家药 品监督管理局下发的《受理通知书》，由公司提交的"小儿连花清感颗粒"新药注册上市申请已获正式受 理。 小儿连花清感颗粒是公司自主研制的中药创新药，其功能主治为：清感解表，宣肺泄热。用于儿童急性 上呼吸道感染风热感冒证，症见发热，鼻塞，咽喉肿痛，咳嗽，恶风，喷嚏、流涕，头痛，肌肉酸痛， 舌淡红或红，苔薄黄，脉浮数。 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 近日，石家庄以岭药业股份有限公司（以下简称"公司"）收到国家药品监 督管理局下发的《受理通知书》，由公司提交的"小儿连花清感颗粒"新药注册 上市申请已获正式受理。现就相关事项公告如下： 一、受理通知书基本内容 申 请 人：石家庄以岭药业股份有限公司 申请事项：境内生产药品注册上市许可 证券代码：002603 证券简称：以岭药业 公告编号：2025-030 石家庄以岭药业股份有限公司 关于收到药品注册申请受理通知书的公告 小儿连花清感颗粒是公司自主研制的中药创新药，其功能主治为：清感解表， 宣肺泄热。用于儿童急性上呼吸道感染风热感冒证，症见发热，鼻塞，咽喉肿痛， 咳嗽，恶风，喷嚏、流涕，头痛，肌肉酸痛，舌淡红或红，苔薄黄，脉浮数。 三、对公司的影响及主要风险提示 根据国家药品注册相关的法律法规要求，上述药品在获国家药品监督管理局 注册申请受理后将转入国家药品监督管理局药品审评中心接受技术审评、现场核 查、抽样检验等一系列环节，完成时间、审批结果均具有一定的不确定性，因此 上述产品获得注册受理对公司近期业绩不会产生影 ...

人民财讯8月19日电，以岭药业（002603）8月19日晚间公告，公司近日收到国家药品监督管理局下发的 《受理通知书》，公司提交的"小儿连花清感颗粒"新药注册上市申请已获正式受理。该药品是公司自主 研制的中药创新药，其功能主治为：清感解表，宣肺泄热。用于儿童急性上呼吸道感染风热感冒证。 ...

以岭药业公告称，公司收到国家药品监督管理局下发的《受理通知书》，公司提交的"小儿连花清感颗 粒"新药注册上市申请已获正式受理。该药品为公司自主研制的中药创新药，功能主治为清感解表，宣 肺泄热，用于儿童急性上呼吸道感染风热感冒证。 ...

Group 1 - Yiling Pharmaceutical (002603) signed a cooperation agreement with Ant Group's healthcare division on August 17 [1] - The collaboration aims to integrate resources from both companies to focus on patient needs [1] - The goal is to create a leading digital content ecosystem in the pharmaceutical and health sector in China [1]